Centessa is a clinical-stage pharmaceutical company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients.

Centessa aims to bring impactful new medicines to patients by combining the strengths of an asset-centric model with the benefits of scale and diversification typical of larger R&D organizations.

Centessa was founded in 2020 by Medicxi. The company is headquartered in Cambridge, MA and London, UK.


Centessa applies an asset-centric R&D model at scale to advance a portfolio of highly validated programs led by industry leading teams. Each program is developed by an Centessa Subsidiary and supported by a centralized infrastructure and the Centessa management team.


Centessa's programs range from discovery-stage to late-stage development and include diverse therapeutic areas including oncology, hematology, immunology/inflammation, neuroscience, hepatology, pulmonology and nephrology.


Centessa raised $250M in an oversubscribed Series A financing on Feb 16, 2021. The round was led by General Atlantic and co-led by Vida Ventures and Janus Henderson Investors. Other investors include Boxer Capital, Cormorant Asset Management, T. Rowe Price Associates, Venrock Healthcare, among many also participated in the round.



  • Year founded: 2020
  • Funding Info: $250M over 1 Round (Funding Type: Series A)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Cambridge
  • State: Massachusetts
  • Country: United States
Related businesses